HK Stock Market Move | HANSOH PHARMA(03692) rose over 7%, with net profit for the full year increasing by 27.07% year-on-year. The proportion of revenue from innovative drugs and partnerships has increased to 82%.

HANSOH PHARMA (03692) rose more than 7%, as of the time of publication, it is up by 6.89% to 35.36 Hong Kong dollars, with a total turnover of 1.93 billion Hong Kong dollars. On the news front, HANSOH PHARMA recently released its performance for the year 2025, with the group achieving revenue of 15.028 billion yuan, a year-on-year increase of 22.57%; the net profit attributable to the owners of the parent company was 5.55 billion yuan, a year-on-year increase of 27.07%; it plans to distribute a final dividend of 20 cents per share. It is worth mentioning that as of the end of the year 2025, sales revenue from innovative drugs and collaborative products was approximately 12.354 billion yuan, accounting for about 82.2% of total revenue, becoming the core driving force for sustainable performance growth of the group.